The evaluation of TILs has been shown to represent a reliable surrogate of the immune anti-tumour activity and a robust independent prognostic biomarker in breast cancer patients, especially in the TNBC and HER2-positive breast cancer subtypes30,31. The gene discussed is ERBB2; the disease is breast carcinoma.